| |
Period 1 (N = 781)
|
Period 2 (N = 988)
|
Period 3 (N = 1171)
|
Total (N = 2940)
|
|---|
|
n =
|
% (95% CI)
|
n =
|
% (95% CI)
|
n =
|
% (95% CI)
|
n =
|
% (95% CI)
|
|---|
|
Analysis method
|
|
RT-PCR
|
443
|
56.7 (53.2–60.2)
|
298
|
30.2 (27.4–33.1)
|
111
|
9.5 (7.9–11.3)
|
852
|
29.0 (27.4–30.6)
|
|
RAD test
|
1
|
0.1 (0.007–0.7)
|
506
|
51.2 (48.1–54.3)
|
395
|
33.7 (31.1–36.5)
|
902
|
30.7 (29.0–32.4)
|
|
VitaPCR
|
0
|
0.0 (0.0–0.5)
|
4
|
0.4 (0.2–1.0)
|
435
|
37.1 (34.4–40.0)
|
439
|
14.9 (13.7–16.3)
|
|
Total
|
444
|
56.9 (53.4–60.3)
|
650
|
65.8 (62.8–68.7)
|
772
|
65.9 (63.2–68.6)
|
1866
|
63.5 (61.7–65.2)
|
|
Participants tested with multiple methods
|
|
Antigen and RT-PCR
|
0
|
0.0 (0.0–0.5)
|
152
|
15.4 (13.3–17.8)
|
34
|
2.9 (2.1–4.0)
|
186
|
6.3 (5.5–7.3)
|
|
Antigen and Vita-PCR
|
0
|
0.0 (0.0–0.5)
|
0
|
0.0 (0.0–0.4)
|
75
|
6.4 (5.1–8.0)
|
75
|
2.6 (2.0–3.2)
|
|
VitaPCR and RT-PCR
|
0
|
0.0 (0.0–0.5)
|
2
|
0.2 (0.04–0.7)
|
44
|
3.8 (2.8–5.0)
|
46
|
1.6 (1.2–2.1)
|
|
RAD, VitaPCR and RT-PCR
|
0
|
0.0 (0.0–0.5)
|
2
|
0.2 (0.04–0.7)
|
9
|
0.8 (0.4–1.5)
|
11
|
0.4 (0.2–0.7)
|
- The use of Real-time polymerase chain reaction (RT-PCR) at the core laboratory decreased significantly between each study period as the point of care rapid antigen detection (RAD) test and point of care rapid RT-PCR VitaPCR were introduced in Period 2 and 3 respectively. Number of tests are presented with percentages (%) of total participants in each period and 95% confidence intervals (CI)
